title: Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of Streptococcus pneumoniae than estimated by conventional methods alone.
abstract: In up to half of all cases of community-acquired pneumonia (CAP), no pathogen can be identified with conventional diagnostic methods. The most common identified causative agent is Streptococcus pneumoniae. In this study, pneumococcal antibody responses during CAP were analyzed to estimate the contribution of the pneumococcus to all cases of CAP for epidemiological purposes. Pneumococcal antibodies against 14 different serotypes were measured in serum of hospitalized CAP patients. Patients participated in one of two consecutive clinical trials in a general 600-bed teaching hospital in the Netherlands (between October 2004 and June 2009). A significant pneumococcal immune response was defined as at least a 2-fold increase in antibody concentrations against a single serotype between an early (day 1) and a late (day 30) serum sample of each patient with an end concentration above 0.35 μg/ml. A total of 349 adult CAP patients participated in two consecutive clinical trials. For 200 patients, sufficient serum samples were available to determine antibody responses: 62 pneumococcal pneumonia patients, 57 nonpneumococcal pneumonia patients, and 81 patients with an unidentified causative agent. A significant immune response was detected in 45% (28/62 patients) of pneumococcal pneumonia patients, in 5% (3/57) of nonpneumococcal pneumonia patients, and in 28% (23/81) of patients with an unidentified causative agent. The estimated contribution of pneumococci in patients with an unidentified causative agent was calculated to be 57% (95% confidence interval, 36 to 86%). A substantial fraction of pneumococcal pneumonia patients do not elicit a serotype-specific immune response.
authors.affiliation: Department of Medical Microbiology & Immunology, Sint Antonius Hospital, P.O. Box 2500, 3430 EM Nieuwegein, The Netherlands. s.van.mens@antoniusziekenhuis.nl
authors.forename: Suzan P
authors.initials: SP
authors.lastname: van Mens
authors.forename: Sabine C A
authors.initials: SC
authors.lastname: Meijvis
authors.forename: Henrik
authors.initials: H
authors.lastname: Endeman
authors.forename: Heleen
authors.initials: H
authors.lastname: van Velzen-Blad
authors.forename: Douwe H
authors.initials: DH
authors.lastname: Biesma
authors.forename: Jan C
authors.initials: JC
authors.lastname: Grutters
authors.forename: Bart J M
authors.initials: BJ
authors.lastname: Vlaminckx
authors.forename: Ger T
authors.initials: GT
authors.lastname: Rijkers
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial; D017714:Community-Acquired Infections / Q000453:epidemiology* / Q000276:immunology / Q000382:microbiology*; D005260:Female; D006760:Hospitalization; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D018410:Pneumonia, Bacterial / Q000453:epidemiology* / Q000276:immunology / Q000382:microbiology*; D015995:Prevalence; D013296:Streptococcus pneumoniae / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial